Becopoulos T, Kranides A, Mandalaki-Yianitsiotis T, Louizou K, Panagiotopoulou E, Dimopoulos C
J Urol (Paris). 1980;86(6):467-70.
Carcinoma of the prostate, above all when accompanied by bone metastases, may be associated with a disseminated intravascular coagulation syndrome. The problem was to determine whether even in the absence of metastases the coagulation state of prostatic carcinoma patients predisposes them to disseminated intravascular coagulation. The authors compared coagulation equilibrium in 13 patients with a prostatic adenoma and 21 with carcinoma of the prostate free of metastases or infection. Fibrin breakdown product levels were abnormally high in 85.7 % of the carcinoma patients (as against 46.2 % of the adenoma sufferers). Clotting factor XIII was decreased in 70 % of carcinoma patients (as against 48.5 % of those with an adenoma). One prostatic carcinoma patient in four shows evidence of latent intravascular coagulation even in the absence of bone metastases. This prevalence justifies thorough coagulation studies in all patients with carcinoma of the prostate.
前列腺癌,尤其是伴有骨转移时,可能与弥散性血管内凝血综合征相关。问题在于确定即使在没有转移的情况下,前列腺癌患者的凝血状态是否使他们易于发生弥散性血管内凝血。作者比较了13例前列腺腺瘤患者和21例无转移或感染的前列腺癌患者的凝血平衡。85.7%的前列腺癌患者纤维蛋白降解产物水平异常升高(而腺瘤患者为46.2%)。70%的前列腺癌患者凝血因子XIII降低(而腺瘤患者为48.5%)。即使在没有骨转移的情况下,四分之一的前列腺癌患者有潜在血管内凝血的迹象。这种患病率证明对所有前列腺癌患者进行全面的凝血研究是合理的。